Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome

Aim. Analysis of the effectiveness of therapy for non-alcoholic fatty liver disease (NAFLD) with severe asthenic syndrome. Materials and methods. In the period from 2017 to 2019, on the basis of the gastroenterology center of the Vishnevsky 3-rd Central Military Clinical Hospital, 247 patients wi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aleksandr I. Pavlov, Aleksandr F. Ivolgin, Sergei V. Katenko, Mikhail N. Eremin, Alevtina I. Molodova, Olga B. Levchenko, Aram G. Karakozov
Formato:	article
Lenguaje:	RU
Publicado:	"Consilium Medicum" Publishing house 2021
Materias:	non-alcoholic fatty liver disease non-alcoholic steatohepatitis asthenic syndrome asthenia mfi-20 diagnosis therapy treatment Medicine R
Acceso en línea:	https://doaj.org/article/b5c2b7d54dbf45fd8ab12615537db6d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b5c2b7d54dbf45fd8ab12615537db6d8
record_format	dspace
spelling	oai:doaj.org-article:b5c2b7d54dbf45fd8ab12615537db6d82021-12-01T12:22:36ZDiagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome0040-36602309-534210.26442/00403660.2021.08.200974https://doaj.org/article/b5c2b7d54dbf45fd8ab12615537db6d82021-08-01T00:00:00Zhttps://ter-arkhiv.ru/0040-3660/article/viewFile/79423/60069https://doaj.org/toc/0040-3660https://doaj.org/toc/2309-5342Aim. Analysis of the effectiveness of therapy for non-alcoholic fatty liver disease (NAFLD) with severe asthenic syndrome. Materials and methods. In the period from 2017 to 2019, on the basis of the gastroenterology center of the Vishnevsky 3-rd Central Military Clinical Hospital, 247 patients with NAFLD, including those at the stage of steatohepatitis, and severe asthenic syndrome were examined and treated. The main group included 124 patients, the control group 123 patients. All patients underwent complex laboratory and instrumental diagnostics and neuropsychological research using the subjective asthenia assessment scale (MFI-20). In both groups, domestic drugs were included in the therapy regimen: from the 1st to the 10th day, Heptrong solution 3 ml intramuscularly in the morning; from the 1st to the 60th day UDCA 250 mg orally, 3 capsules at bedtime, Omega-3 forte 1000 mg, 2 capsules in the morning with meals. In group I patients received additionally from the 1st to the 10th day intravenous drip Cytoflavin 10 ml + 0.9% NaCl solution 200 ml; pentoxifylline solution 5 ml + 0.9% NaCl solution 200 ml. Then, from the 11th to the 60th day, Cytoflavin inside, 2 tablets 2 times a day. Pentoxifylline inside 400 mg 1 tablet 3 times a day. All patients underwent neuropsychological examination using the subjective asthenia rating scale (MFI-20). Results. The effectiveness of treatment in patients of both groups was assessed by clinical, laboratory data and neuropsychological studies. In the main group, a significant reduction in asthenic syndrome was achieved against the background of diagnosed NAFLD compared with the control group. Conclusion. The early inclusion of patients with NAFLD and severe asthenic syndrome in the treatment regimen, in addition to the basic therapy of Cytoflavin, achieved a significantly high therapeutic effect in the form of normalization of the main clinical, laboratory and instrumental parameters, as well as a significant reduction in the manifestations of asthenia.Aleksandr I. PavlovAleksandr F. IvolginSergei V. KatenkoMikhail N. EreminAlevtina I. MolodovaOlga B. LevchenkoAram G. Karakozov"Consilium Medicum" Publishing housearticlenon-alcoholic fatty liver diseasenon-alcoholic steatohepatitisasthenic syndromeastheniamfi-20diagnosistherapytreatmentMedicineRRUТерапевтический архив, Vol 93, Iss 8, Pp 890-896 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	non-alcoholic fatty liver disease non-alcoholic steatohepatitis asthenic syndrome asthenia mfi-20 diagnosis therapy treatment Medicine R
spellingShingle	non-alcoholic fatty liver disease non-alcoholic steatohepatitis asthenic syndrome asthenia mfi-20 diagnosis therapy treatment Medicine R Aleksandr I. Pavlov Aleksandr F. Ivolgin Sergei V. Katenko Mikhail N. Eremin Alevtina I. Molodova Olga B. Levchenko Aram G. Karakozov Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
description	Aim. Analysis of the effectiveness of therapy for non-alcoholic fatty liver disease (NAFLD) with severe asthenic syndrome. Materials and methods. In the period from 2017 to 2019, on the basis of the gastroenterology center of the Vishnevsky 3-rd Central Military Clinical Hospital, 247 patients with NAFLD, including those at the stage of steatohepatitis, and severe asthenic syndrome were examined and treated. The main group included 124 patients, the control group 123 patients. All patients underwent complex laboratory and instrumental diagnostics and neuropsychological research using the subjective asthenia assessment scale (MFI-20). In both groups, domestic drugs were included in the therapy regimen: from the 1st to the 10th day, Heptrong solution 3 ml intramuscularly in the morning; from the 1st to the 60th day UDCA 250 mg orally, 3 capsules at bedtime, Omega-3 forte 1000 mg, 2 capsules in the morning with meals. In group I patients received additionally from the 1st to the 10th day intravenous drip Cytoflavin 10 ml + 0.9% NaCl solution 200 ml; pentoxifylline solution 5 ml + 0.9% NaCl solution 200 ml. Then, from the 11th to the 60th day, Cytoflavin inside, 2 tablets 2 times a day. Pentoxifylline inside 400 mg 1 tablet 3 times a day. All patients underwent neuropsychological examination using the subjective asthenia rating scale (MFI-20). Results. The effectiveness of treatment in patients of both groups was assessed by clinical, laboratory data and neuropsychological studies. In the main group, a significant reduction in asthenic syndrome was achieved against the background of diagnosed NAFLD compared with the control group. Conclusion. The early inclusion of patients with NAFLD and severe asthenic syndrome in the treatment regimen, in addition to the basic therapy of Cytoflavin, achieved a significantly high therapeutic effect in the form of normalization of the main clinical, laboratory and instrumental parameters, as well as a significant reduction in the manifestations of asthenia.
format	article
author	Aleksandr I. Pavlov Aleksandr F. Ivolgin Sergei V. Katenko Mikhail N. Eremin Alevtina I. Molodova Olga B. Levchenko Aram G. Karakozov
author_facet	Aleksandr I. Pavlov Aleksandr F. Ivolgin Sergei V. Katenko Mikhail N. Eremin Alevtina I. Molodova Olga B. Levchenko Aram G. Karakozov
author_sort	Aleksandr I. Pavlov
title	Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
title_short	Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
title_full	Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
title_fullStr	Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
title_full_unstemmed	Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
title_sort	diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
publisher	"Consilium Medicum" Publishing house
publishDate	2021
url	https://doaj.org/article/b5c2b7d54dbf45fd8ab12615537db6d8
work_keys_str_mv	AT aleksandripavlov diagnosticsandtreatmentofnonalcoholicfattyliverdiseasewithconcomitantasthenicsyndrome AT aleksandrfivolgin diagnosticsandtreatmentofnonalcoholicfattyliverdiseasewithconcomitantasthenicsyndrome AT sergeivkatenko diagnosticsandtreatmentofnonalcoholicfattyliverdiseasewithconcomitantasthenicsyndrome AT mikhailneremin diagnosticsandtreatmentofnonalcoholicfattyliverdiseasewithconcomitantasthenicsyndrome AT alevtinaimolodova diagnosticsandtreatmentofnonalcoholicfattyliverdiseasewithconcomitantasthenicsyndrome AT olgablevchenko diagnosticsandtreatmentofnonalcoholicfattyliverdiseasewithconcomitantasthenicsyndrome AT aramgkarakozov diagnosticsandtreatmentofnonalcoholicfattyliverdiseasewithconcomitantasthenicsyndrome
_version_	1718405194701602816

Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome

Ejemplares similares